To this end, IDH-associated MGPs predicted for CNS-GBM/Oligo and TCGA-LAML were compared to examine the metabolic effects of IDH mutation in these two cancer types (Additional file 1: Fig. S10). This evidence concerns the gene IDH2 and glioblastoma.